Asthma and COPD Drugs Industry
PORTLAND, OREGON, UNITED STATES, May 4, 2023 /EINPresswire.com/ — Asthma and COPD are chronic respiratory diseases that affect millions of people worldwide. Both conditions can cause difficulty in breathing, coughing, wheezing, and other respiratory symptoms. Fortunately, there are many drugs available to manage the symptoms of asthma and COPD, and the market for these drugs is expected to grow significantly in the coming years.
๐๐๐๐จ๐ซ๐๐ข๐ง๐ ๐ญ๐จ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก, ๐ญ๐ก๐ ๐๐ฌ๐ญ๐ก๐ฆ๐ ๐๐ง๐ ๐๐๐๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $32988.7 ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง 2020 ๐๐ง๐ ๐ข๐ฌ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $52049.54 ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ 2030, ๐ซ๐๐ ๐ข๐ฌ๐ญ๐๐ซ๐ข๐ง๐ ๐ ๐๐๐๐ ๐จ๐ 4.64% ๐๐ซ๐จ๐ฆ 2021 ๐ญ๐จ 2030. This growth is attributed to several factors, including the increasing prevalence of asthma and COPD, rising demand for effective treatment options, and advancements in drug development.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ ๐๐ญ: https://www.alliedmarketresearch.com/request-sample/311
Key Market Players
1. ๐๐๐๐จ๐ญ๐ญ ๐๐๐๐จ๐ซ๐๐ญ๐จ๐ซ๐ข๐๐ฌ
2. ๐๐ฌ๐ญ๐ซ๐๐๐๐ง๐๐๐ ๐๐ฅ๐
3. ๐๐จ๐๐ก๐ซ๐ข๐ง๐ ๐๐ซ ๐๐ง๐ ๐๐ฅ๐ก๐๐ข๐ฆ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฆ๐๐
4. ๐๐ฅ๐๐ฑ๐จ๐ฌ๐ฆ๐ข๐ญ๐ก๐ค๐ฅ๐ข๐ง๐ ๐๐ฅ๐
5. ๐๐จ๐๐๐ฆ๐๐ง๐ง-๐๐ ๐๐จ๐๐ก๐
6. ๐๐จ๐ฏ๐๐ซ๐ญ๐ข๐ฌ ๐๐
7. ๐๐ซ๐ ๐๐ง๐จ๐ง
8. ๐๐๐ง๐จ๐๐ข
9. ๐๐๐ฏ๐ ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐๐ฌ
10. ๐๐๐๐ญ๐ฎ๐ซ๐ ๐๐ซ๐จ๐ฎ๐ฉ
๐๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐จ๐ซ ๐๐ฌ๐ญ๐ก๐ฆ๐ ๐๐ง๐ ๐๐๐๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ง ๐๐ ๐๐ง๐๐ฅ๐ฒ๐ณ๐๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ญ๐ก๐ ๐ญ๐ฒ๐ฉ๐ ๐จ๐ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ง๐ ๐ฆ๐๐๐ข๐๐๐ญ๐ข๐จ๐ง ๐๐ฅ๐๐ฌ๐ฌ.
By Diseases:
Asthma and COPD are two distinct respiratory diseases, but they share some common symptoms such as coughing, wheezing, and shortness of breath. The market for asthma and COPD drugs can be segmented based on the prevalence of these diseases. According to the World Health Organization (WHO), asthma affects around 339 million people worldwide, while COPD affects around 251 million people globally.
By Medication Class:
The market for asthma and COPD drugs can also be analyzed based on the type of medication class. There are several classes of drugs available for the treatment of asthma and COPD, including combination drugs, short-acting beta agonists (SABA), long-acting beta agonists (LABA), leukotriene antagonists (LTA), anticholinergics, and others.
Combination Drugs: Combination drugs are used to manage both asthma and COPD symptoms. These drugs usually contain a combination of two or more medications, such as a bronchodilator and a corticosteroid. Some examples of combination drugs include fluticasone/salmeterol and budesonide/formoterol.
Short-Acting Beta Agonists (SABA): SABAs are bronchodilators that work quickly to relieve symptoms of asthma and COPD. These drugs are usually used as a rescue medication during an acute exacerbation of symptoms. Examples of SABAs include albuterol and levalbuterol.
Long-Acting Beta Agonists (LABA): LABAs are also bronchodilators that work to relax the muscles in the airways. These drugs are usually used as maintenance therapy to prevent symptoms of asthma and COPD. Examples of LABAs include salmeterol and formoterol.
Leukotriene Antagonists (LTA): LTAs are a class of drugs that work by blocking the action of leukotrienes, which are molecules that cause inflammation in the airways. These drugs are used to prevent symptoms of asthma and COPD. Examples of LTAs include montelukast and zafirlukast.
Anticholinergics: Anticholinergics work by relaxing the muscles around the airways, which helps to open them up and improve breathing. These drugs are used to treat COPD and can also be used to treat asthma. Examples of anticholinergics include ipratropium and tiotropium.
Others: There are also other classes of drugs that are used to manage symptoms of asthma and COPD, such as corticosteroids and immunomodulators. Corticosteroids work by reducing inflammation in the airways, while immunomodulators target specific immune cells to reduce inflammation. Examples of corticosteroids include budesonide and fluticasone, while omalizumab is an example of an immunomodulator.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/311
๐๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐จ๐ซ ๐๐ฌ๐ญ๐ก๐ฆ๐ ๐๐ง๐ ๐๐๐๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ง ๐๐ฅ๐ฌ๐จ ๐๐ ๐๐ง๐๐ฅ๐ฒ๐ณ๐๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ ๐๐จ๐ ๐ซ๐๐ฉ๐ก๐ข๐ ๐ซ๐๐ ๐ข๐จ๐ง๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ ๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐, ๐๐ฎ๐ซ๐จ๐ฉ๐, ๐๐ฌ๐ข๐ ๐๐๐๐ข๐๐ข๐, ๐๐ง๐ ๐๐๐๐๐ (๐๐๐ญ๐ข๐ง ๐๐ฆ๐๐ซ๐ข๐๐, ๐๐ข๐๐๐ฅ๐ ๐๐๐ฌ๐ญ, ๐๐ง๐ ๐๐๐ซ๐ข๐๐).
North America: The North American market is expected to dominate the asthma and COPD drugs market, primarily due to the high prevalence of these diseases and the presence of major pharmaceutical companies in the region. The United States is the largest market for asthma and COPD drugs in North America, followed by Canada and Mexico.
Europe: Europe is expected to be the second-largest market for asthma and COPD drugs, driven by the increasing prevalence of these diseases, growing geriatric population, and the availability of advanced healthcare infrastructure. Germany, France, the UK, Italy, and Spain are the major markets for asthma and COPD drugs in Europe.
Asia Pacific: The Asia Pacific market for asthma and COPD drugs is expected to grow significantly in the coming years, driven by the increasing prevalence of these diseases in the region, growing healthcare expenditure, and the presence of a large patient population. Japan, China, India, South Korea, and Australia are the major markets for asthma and COPD drugs in the Asia Pacific region.
LAMEA: The LAMEA market for asthma and COPD drugs is also expected to grow significantly in the coming years, driven by the increasing prevalence of these diseases, growing healthcare expenditure, and the presence of major pharmaceutical companies in the region. Brazil, Saudi Arabia, and South Africa are the major markets for asthma and COPD drugs in the LAMEA region.
๐๐๐๐๐๐๐๐ ๐ ๐๐๐ ๐๐๐๐๐๐: https://www.alliedmarketresearch.com/asthma-COPD-drug-market/purchase-options
David Correa
Allied Analytics LLP
+1-800-792-5285
email us here
